NewsBenzingaReported Earlier, Supernus Secures Seven Years Of FDA Orphan-Drug Exclusivity For ONAPGO, Seeks Second Supplier Approval By Mid-2027 Reported Earlier, Supernus Secures Seven Years Of FDA Orphan-Drug Exclusivity For ONAPGO, Seeks Second Supplier Approval By Mid-2027 Benzinga 2026.10.22 07:44 (GMT+0) Open on Benzinga Other news Susquehanna Maintains Positive on United Airlines Holdings, Lowers Price Target to $130 Susquehanna Maintains Positive on Meta Platforms, Raises Price Target to $850 Alpha Tau Medical Inks MoU With Samsung Medical Center In Seoul Regarding Potential Clinical Study In Pancreatic Cancer Patients Susquehanna Maintains Neutral on IBM, Raises Price Target to $256 Susquehanna Maintains Neutral on Genpact, Raises Price Target to $40 Keybanc Maintains Overweight on Meta Platforms, Raises Price Target to $905
Alpha Tau Medical Inks MoU With Samsung Medical Center In Seoul Regarding Potential Clinical Study In Pancreatic Cancer Patients
